Essential Thrombocythemia - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Essential Thrombocythemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Essential Thrombocythemia - Pipeline Review, H1 2015’, provides an overview of the Essential Thrombocythemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia - Overview 8
Pipeline Products for Essential Thrombocythemia - Comparative Analysis 9
Essential Thrombocythemia - Therapeutics under Development by Companies 10
Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes 11
Essential Thrombocythemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Essential Thrombocythemia - Products under Development by Companies 15
Essential Thrombocythemia - Products under Investigation by Universities/Institutes 16
Essential Thrombocythemia - Companies Involved in Therapeutics Development 17
Aop Orphan Pharmaceuticals AG 17
Biogenomics Limited 18
Galena Biopharma, Inc. 19
Gilead Sciences, Inc. 20
Incyte Corporation 21
Italfarmaco S.p.A. 22
Novartis AG 23
Onconova Therapeutics, Inc. 24
PharmaEssentia Corporation 25
Essential Thrombocythemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
anagrelide hydrochloride CR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
anagrelide hydrochloride PR - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
erismodegib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
givinostat - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
interferon alfa-2b (recombinant) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
momelotinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
peginterferon alfa-2b - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rigosertib sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ruxolitinib phosphate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Essential Thrombocythemia - Recent Pipeline Updates 58
Essential Thrombocythemia - Dormant Projects 78
Essential Thrombocythemia - Discontinued Products 79
Essential Thrombocythemia - Product Development Milestones 80
Featured News & Press Releases 80
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 80
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 80
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 81
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 82
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for Essential Thrombocythemia, H1 2015 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H1 2015 17
Essential Thrombocythemia - Pipeline by Biogenomics Limited, H1 2015 18
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H1 2015 19
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H1 2015 20
Essential Thrombocythemia - Pipeline by Incyte Corporation, H1 2015 21
Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H1 2015 22
Essential Thrombocythemia - Pipeline by Novartis AG, H1 2015 23
Essential Thrombocythemia - Pipeline by Onconova Therapeutics, Inc., H1 2015 24
Essential Thrombocythemia - Pipeline by PharmaEssentia Corporation, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H1 2015 58
Essential Thrombocythemia - Dormant Projects, H1 2015 78
Essential Thrombocythemia - Discontinued Products, H1 2015 79